Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Mafenide Acetate

FDA-approved product (cream, topical), marketed as Mafenide Acetate, Sulfamylon.

Registered studies
6
Lab records
3
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Mafenide Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Burn

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sulfonamides
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC D06BA03

Repurposing investigation

Mafenide Acetate is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA8.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli13.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae4.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis86.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

6registered studies name this medicine, for any condition. See them below.

Experimental

  • M. tuberculosis: measured active in 3 of 3 lab records
Open Mafenide Acetate in ChEMBL Registered studies below
Show the 3 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Mafenide Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety Study of a Novel Wearable Phototherapy System for the Management of Acute Burn Wounds

    NCT03948360 · start 2017-09-07

    Registered record
    Registry ID
    NCT03948360
    Conditions
    Burn Wound
    Interventions
    Low-Irradiance Monochromatic Biostimulation (LIMB) Device; Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2017-09-07
    Completion
    2019-12-31
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBurn Wound
    InterventionLow-Irradiance Monochromatic Biostimulation (LIMB) Device; Standard of Care
    PhaseNot applicable
    Registry statusUnknown

  • Patients Response to Early Switch To Oral:Osteomyelitis Study

    NCT02099240 · start 2014-03-06

    Registered record
    Registry ID
    NCT02099240
    Conditions
    Osteomyelitis
    Interventions
    oral antibiotics; intravenous antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2014-03-06
    Completion
    2018-11-07
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteomyelitis
    Interventionoral antibiotics; intravenous antibiotics
    PhaseEarly phase 1
    Registry statusTerminated

  • Study of Low Adherent Dressing Versus the Standard of Care for the Management of Skin Grafts Over Thermal Burns

    NCT01654094 · start 2012-10

    Registered record
    Registry ID
    NCT01654094
    Conditions
    Burns; Skin Burn Requiring Skin Graft
    Interventions
    P6 Low Adherent Dressing; Standard of Care (SOC)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-10
    Completion
    2017-09-29
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBurns; Skin Burn Requiring Skin Graft
    InterventionP6 Low Adherent Dressing; Standard of Care (SOC)
    PhaseNot applicable
    Registry statusCompleted

  • Vashe Wound Therapy Study

    NCT00586729 · start 2009-07

    Registered record
    Registry ID
    NCT00586729
    Conditions
    Burns
    Interventions
    Vashe; Mafenide acetate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-07
    Completion
    2010-11
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBurns
    InterventionVashe; Mafenide acetate
    PhaseNot applicable
    Registry statusCompleted

  • Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group

    NCT00634166 · start 2007-09

    Registered record
    Registry ID
    NCT00634166
    Conditions
    Burns
    Interventions
    Sulfamylon® For 5 % Topical Solution; Topical Antimicrobial/Antifungal Medications
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2007-09
    Completion
    2014-04
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBurns
    InterventionSulfamylon® For 5 % Topical Solution; Topical Antimicrobial/Antifungal Medications
    PhasePhase 4
    Registry statusTerminated

  • Study of the Treatment of Burn Wounds With Antimicrobial Topical Soaks

    NCT00675922 · start 1995-07

    Registered record
    Registry ID
    NCT00675922
    Conditions
    Burn
    Interventions
    Sulfamylon 5% and Silver Nitrate Soaks
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    1995-07
    Completion
    2008-05
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBurn
    InterventionSulfamylon 5% and Silver Nitrate Soaks
    PhasePhase 2 / Phase 3
    Registry statusTerminated